PMID- 26819103 OWN - NLM STAT- MEDLINE DCOM- 20170224 LR - 20181113 IS - 1619-7089 (Electronic) IS - 1619-7070 (Linking) VI - 43 IP - 7 DP - 2016 Jul TI - Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. PG - 1258-66 LID - 10.1007/s00259-016-3319-3 [doi] AB - CONTEXT: Somatostatin receptor scintigraphy with (111)In-pentetreotide (SRS) is used to detect duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type 1 (MEN1). However, SRS has limited sensitivity for this purpose. Positron emission tomography/computed tomography (PET/CT) with (68)Ga-DOTA-TOC has a higher rate of sporadic dpNETs detection than SRS but there is little data for dpNETs detection in MEN1. PURPOSE: To compare the performances of (68)Ga-DOTA-TOC PET/CT, SRS and contrast-enhanced computed tomography (CE-CT) to diagnose dpNETs in MEN1. DESIGN AND SETTING: Single-institution prospective comparative study PATIENTS AND METHODS: Nineteen consecutive MEN1 patients (aged 47 +/- 13 years) underwent (68)Ga-DOTA-TOC PET/CT, SRS, and CE-CT within 2 months in random order. Blinded readings of images were performed separately by experienced physicians. Unblinded analysis of CE-CT, combined with additional magnetic resonance imaging, endoscopic-ultrasound, (18)F-2-fluoro-deoxy-D-glucose ((18)F-FDG) PET/CT or histopathology results served as reference standard for dpNETs diagnosis. RESULTS: The sensitivity of (68)Ga-DOTA-TOC PET/CT, SRS, and CE-CT was 76, 20, and 60 %, respectively (p < 0.0001). All the true-positive lesions detected by SRS were also depicted on (68)Ga-DOTA-TOC PET/CT. (68)Ga-DOTA-TOC PET/CT detected lesions of smaller size than SRS (10.7 +/- 7.6 and 15.2 +/- 5.9 mm, respectively, p < 0.03). False negatives of (68)Ga-DOTA-TOC PET/CT included small dpNETs (<10 mm) and (18)F-FDG PET/CT positive aggressive dpNETs. No false positives were recorded. In addition, whole-body mapping with (68)Ga-DOTA-TOC PET/CT identified extra-abdominal MEN1-related tumors including one neuroendocrine thymic carcinoma identified by the three imaging procedures, one bronchial carcinoid undetected by CE-CT and three meningiomas undetected by SRS. CONCLUSIONS: Owing to higher diagnostic performance, (68)Ga-DOTA-TOC PET/CT (or alternative (68)Ga-labeled somatostatin analogues) should replace (111)In-pentetreotide in the investigation of MEN1 patients. FAU - Morgat, Clement AU - Morgat C AD - CNRS, INCIA, UMR 5287, 33000, Bordeaux, France. clement.morgat@chu-bordeaux.fr. AD - University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France. clement.morgat@chu-bordeaux.fr. AD - Department of Nuclear Medicine, University Hospital of Bordeaux, 33000, Bordeaux, France. clement.morgat@chu-bordeaux.fr. FAU - Velayoudom-Cephise, Fritz-Line AU - Velayoudom-Cephise FL AD - Department of Endocrinology, USN Haut-Leveque, 33604, Pessac, France. FAU - Schwartz, Paul AU - Schwartz P AD - Department of Nuclear Medicine, University Hospital of Bordeaux, 33000, Bordeaux, France. FAU - Guyot, Martine AU - Guyot M AD - Department of Nuclear Medicine, University Hospital of Bordeaux, 33000, Bordeaux, France. FAU - Gaye, Delphine AU - Gaye D AD - Department of Radiology, University Hospital of Bordeaux, 33604, Pessac, France. FAU - Vimont, Delphine AU - Vimont D AD - CNRS, INCIA, UMR 5287, 33000, Bordeaux, France. AD - University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France. FAU - Schulz, Jurgen AU - Schulz J AD - CNRS, INCIA, UMR 5287, 33000, Bordeaux, France. AD - University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France. FAU - Mazere, Joachim AU - Mazere J AD - CNRS, INCIA, UMR 5287, 33000, Bordeaux, France. AD - University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France. AD - Department of Nuclear Medicine, University Hospital of Bordeaux, 33000, Bordeaux, France. FAU - Nunes, Marie-Laure AU - Nunes ML AD - Department of Endocrinology, USN Haut-Leveque, 33604, Pessac, France. FAU - Smith, Denis AU - Smith D AD - Department of Oncology, University Hospital of Bordeaux, 33000, Bordeaux, France. FAU - Hindie, Elif AU - Hindie E AD - CNRS, INCIA, UMR 5287, 33000, Bordeaux, France. AD - University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France. AD - Department of Nuclear Medicine, University Hospital of Bordeaux, 33000, Bordeaux, France. FAU - Fernandez, Philippe AU - Fernandez P AD - CNRS, INCIA, UMR 5287, 33000, Bordeaux, France. AD - University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France. AD - Department of Nuclear Medicine, University Hospital of Bordeaux, 33000, Bordeaux, France. FAU - Tabarin, Antoine AU - Tabarin A AD - Department of Endocrinology, USN Haut-Leveque, 33604, Pessac, France. LA - eng PT - Clinical Trial PT - Journal Article DEP - 20160128 PL - Germany TA - Eur J Nucl Med Mol Imaging JT - European journal of nuclear medicine and molecular imaging JID - 101140988 RN - 0 (Ga(III)-DOTATOC) RN - 0 (Organometallic Compounds) RN - RWM8CCW8GP (Octreotide) SB - IM MH - Adult MH - Aged MH - Duodenum MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multiple Endocrine Neoplasia Type 1/*complications MH - Neuroendocrine Tumors/*complications/*diagnostic imaging MH - Octreotide/*analogs & derivatives MH - *Organometallic Compounds MH - Pancreatic Neoplasms/*complications/*diagnostic imaging MH - *Positron Emission Tomography Computed Tomography OTO - NOTNLM OT - 111In-pentetreotide SPECT/CT OT - 68Ga-DOTA-TOC PET/CT OT - Contrast-enhanced computed tomography OT - Duodenopancreatic neuroendocrine tumors OT - Multiple endocrine neoplasia type 1 EDAT- 2016/01/29 06:00 MHDA- 2017/02/25 06:00 CRDT- 2016/01/29 06:00 PHST- 2015/10/19 00:00 [received] PHST- 2016/01/15 00:00 [accepted] PHST- 2016/01/29 06:00 [entrez] PHST- 2016/01/29 06:00 [pubmed] PHST- 2017/02/25 06:00 [medline] AID - 10.1007/s00259-016-3319-3 [pii] AID - 10.1007/s00259-016-3319-3 [doi] PST - ppublish SO - Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1258-66. doi: 10.1007/s00259-016-3319-3. Epub 2016 Jan 28.